JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation

  • 0Institute of Molecular Cardiovascular Research, Rheinisch-Westfälische Technisch Hochschule, Aachen, Germany.
Circulation +

|

April 26, 2006

|

April 26, 2006

Related Experiment Videos

Contact us if these videos are not relevant.

View abstract on PubMed

Summary

This summary is machine-generated.

Vascular CD73 limits endothelial activation and monocyte recruitment. CD73 deficiency increases vascular cell adhesion molecule-1 (VCAM-1) and promotes inflammation, but A2A receptor agonist therapy offers protection.

Area Of Science

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background

  • The role of CD73/ecto-5'-nucleotidase in vasoprotection is known, but its specific function in regulating endothelial adhesion molecules and inflammatory monocyte recruitment during vascular injury is unclear.
  • Understanding CD73's impact on endothelial cell activation and inflammatory cell trafficking is crucial for developing targeted therapies for vascular diseases.

Purpose Of The Study

  • To investigate the role of vascular CD73 in controlling endothelial activation and inflammatory monocyte recruitment in the context of vascular injury.
  • To elucidate the molecular mechanisms by which CD73 influences vascular cell adhesion molecule-1 (VCAM-1) expression and monocyte adhesion.

Main Methods

  • Comparison of CD73-deficient (CD73(-/-)) and wild-type mice, assessing VCAM-1 expression, nuclear factor-kappaB (NF-kappaB) activity, and monocyte recruitment in carotid arteries.
  • In vitro studies using endothelial cells (ECs) from CD73(-/-) mice to evaluate VCAM-1 expression and NF-kappaB activation.
  • Wire injury model of carotid arteries to assess neointimal hyperplasia and inflammatory cell infiltration.
  • Treatment with an A2A receptor agonist (ATL-146e) to evaluate its therapeutic potential.

Main Results

  • CD73(-/-) mice exhibited increased VCAM-1 expression and enhanced monocyte adhesion to endothelial cells, mediated by alpha(4beta1) integrin.
  • Wire injury in CD73(-/-) mice led to increased neointimal plaque formation, macrophage content, NF-kappaB activation, and VCAM-1 levels.
  • Treatment with ATL-146e reversed VCAM-1 upregulation and inhibited monocyte arrest in CD73(-/-) ECs, and prevented neointima formation in vivo.

Conclusions

  • Vascular CD73 plays a critical role in suppressing endothelial activation and inflammatory monocyte recruitment.
  • Adenosine generation by CD73, acting via the A2A receptor, is a key mechanism for limiting vascular inflammation.
  • Targeting the CD73-adenosine-A2A receptor pathway holds therapeutic promise for preventing vascular inflammation and neointimal hyperplasia.

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos